INR Goal for Anticoagulation in Atrial Fibrillation

Standard INR Target Recommendations

The American College of Cardiology recommends that for patients with nonvalvular atrial fibrillation at high risk of stroke, oral anticoagulation with a vitamin K antagonist (warfarin) should be adjusted to achieve a target INR of 2.0 to 3.0 (target 2.5) 1, 2, 4
This INR range provides maximum protection against ischemic stroke while minimizing the risk of bleeding complications, as supported by the European Heart Journal 5, 6
The same INR target range applies regardless of the pattern of atrial fibrillation (paroxysmal, persistent, or permanent), according to the American College of Cardiology 7, 4
Atrial flutter should be managed with the same anticoagulation strategy and INR targets as atrial fibrillation, as recommended by the American College of Cardiology 2, 7

For elderly patients (≥75 years) at increased risk of bleeding but without frank contraindications to oral anticoagulant therapy, a lower INR target of 2.0 (range 1.6 to 2.5) may be considered, as suggested by the American College of Cardiology 7, 4
For patients with AF who have mechanical heart valves, the target INR should be at least 2.5, with specific targets based on valve type and position, according to the American College of Cardiology 7, 4

The American College of Cardiology recommends that INR should be determined at least weekly during initiation of therapy 2, 7
Once anticoagulation is stable, INR monitoring should occur at least monthly, as recommended by the American College of Cardiology 2
Time in therapeutic range (TTR) should ideally be ≥70% to maximize efficacy and safety, as supported by the American College of Chest Physicians 3, 6
For patients with consistently low time in therapeutic range (TTR <65%), additional measures should be implemented to improve INR control or switching to NOACs should be considered, according to the American College of Chest Physicians 3, 6

Multiple randomized clinical trials have demonstrated that an INR range of 2.0 to 3.0 provides the optimal balance between stroke prevention and bleeding risk, as reported in the European Heart Journal and the Journal of the American College of Cardiology 5, 1
Lower INR targets (1.5-2.0) have been associated with incomplete efficacy, estimated at approximately 80% of that achieved with higher-intensity anticoagulation, according to the European Heart Journal 5

The American College of Chest Physicians recommends that in patients with AF who are eligible for oral anticoagulation, NOACs are now recommended over vitamin K antagonists (VKAs) like warfarin 3, 6
For patients with prior unprovoked bleeding or at high risk of bleeding, specific NOACs (apixaban, edoxaban, or dabigatran 110 mg where available) may be preferable as they demonstrate significantly less major bleeding compared with warfarin, as supported by the American College of Chest Physicians 3, 6
Aspirin alone is not recommended for stroke prevention in AF patients, regardless of stroke risk, according to the American College of Chest Physicians 3